Age-related growth hormone-releasing activity of growth hormone secretagogues in humans

Acta Paediatrica, International Journal of Paediatrics, Supplement

Volumn 86, Issue 423, 1997, Pages 92-96

  Arvat, E ^a   Camanni, F ^a   Ghigo, E ^a  

^a Division of Endocrinology   (Italy)

Author keywords

Ageing; Growth hormone; Growth hormone secretagogues; Growth hormone releasing hormone; Growth hormone releasing peptides

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING PEPTIDE; SOMATOSTATIN; UNCLASSIFIED DRUG; GROWTH PROMOTOR; HEXARELIN; HUMAN GROWTH HORMONE; OLIGOPEPTIDE;

ACROMEGALY; ANOREXIA NERVOSA; CONFERENCE PAPER; CRITICAL ILLNESS; CUSHING DISEASE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HYPERTHYROIDISM; HYPOPHYSIS; HYPOTHALAMUS; HYPOTHYROIDISM; OBESITY; PRIORITY JOURNAL; SHORT STATURE; AGING; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SECRETION;

AGING; DRUG SYNERGISM; GROWTH HORMONE-RELEASING HORMONE; GROWTH SUBSTANCES; HUMAN GROWTH HORMONE; HUMANS; HYPOTHALAMUS; OLIGOPEPTIDES; PITUITARY GLAND;

EID: 0030828665     PISSN: 08035326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (66)

1. Bowers CY, Veeraragavan K, Selhumadhavan K. Atypical growth hormone releasing peptides. In: Bercu BB, Walker RF, editors. Growth hormone II, basic and clinical aspects. New York: Springer-Verlag, 1993:203-22
2. Korbonits M, Grossman AB. Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol Metab 1996;6:43-9
3. Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, et al. Aging and GH-releasing peptides. In: Bercu B, Walker R, editors. Growth hormone secretagogues. New York: Serono Symposia, 1996:415-31
4. Deghenghi R, Bontignon F, Luoni M, Grilli R, Guidi M, Locatelli V. Small peptides as potent releasers of growth hormone. J Ped Endocrinol Metab 1995;8:311-13
5. Smith RG, Cheng K, Pong SS, Hickey G, Jacks T, Butler B, et al. A non-peptidyl GH secretagogue. Science 1993;260:1640-3
6. DeVita RJ, Wyratt MJ. Benzolactam growth hormone secretagogues. Drugs of the future 1996;21:273-81
7. Gertz BJ, Barrett SS, Eisenhandler R, Krupa DA, Wittreich JM, Seibold JR, et al. Growth hormone response in man to L-692,429, a novel non peptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab 1993;77:1393-7
8. Copinschi G, van Onderbergen A, L'Hermite-Baleriaux M, Mendel CM, Caufriez A, Leproult R, et al. Effects of 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab 1996;81:2776-82
9. Elias KA, Ingle GS, Burnier JP, Hammonds RG, McDowell RS, Rawson TE, et al. In vitro characterization of four novel classes of growth hormone-releasing peptide. Endocrinology 1995;136:5694-9
10. Codd EE, Shu AYL, Walker RF. Binding of a growth hormone releasing hexapaptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989;28:1139-44
11. Pong SS, Chaung LYP, Dean DC, Nargunt RP, Patchett AA, Smith RG. Identification of a new G-protein-linked receptor for growth hormone secretacogues. Mol Endocrinol 1996; 10:57-61
12. Muccioli G, Ghe C, Ghigo MC, Arvat E, Papotti M, Boghen MF, et al. Presence of specific receptors for hexarelin, a growth hormone releasing hexapeptide, in human brain and pituitary gland. Endocrinol Metab 1996;3(suppl A):141(abstract)
13. Goth MI, Lyons CE, Canny BY, Thorner MO. Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992;130:939-44
14. Cheng K, Chan WWS, Barreto A, Convey EM, Smith RG. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH, on growth hormone (GH)-releasing factor-stimulated GH refease and intracellular adenosine 3′,5′-monophosphate accumulation in rat primary cell culture. Endocrinology 1989;124:2791-8
15. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273:974-7
16. Jacks T, Hickey G, Judith F, Taylor J, Chen H, Krupa D, et al. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-I, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. J Endocrinol 1994; 143:399-406
17. Hickey GJ, Jacks T, Judith F, Taylor J, Schoen WR, Krupa D, et al. Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles. Endocrinology 1994;134:695-701
18. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990; 70:975-82
19. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. J Clin Endocrinol Metab 1994;78:693-8
20. Korbonits M, Trainer PJ, Besser GM. The effect of an opiate antagonist on the hormonal changes induced by hexarelin. Clin Endocrinol 1995;43:365-71
21. Arvat E, Di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and Cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides 1997 (in press)
22. Mazza E, Ghigo E, Goffi S, Procopio M, Imperiale E, Arvat E, et al. Effect of the potentiation of cholinergic activity on the variability in individual GH response to GHRH. J Endocrinol Invest 1989;12:795-9
23. Penalva A, Pombo M, Carballo A, Barreiro J, Casanueva FF, Dieguez C. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clin Endocrinol 1993;38:87-91
24. Bowers CY. GH releasing peptides. Structure and kinetics. J Pediatr Endocrinol 1993;6:21-31
25. Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi, Boffano GM, et al. Arginine enhances the growth hormone (GH)-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. J Endocrinol Invest 1994;17:157-62
26. Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, et al. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. J Clin Endocrinol Metab 1994;79:1440-3
27. Bellone J, Aimaretti G, Bartolotta E, Benso L, Imbimbo BP, Lenhaerts V, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty. J Clin Endocrinol Metab 1995;80:1090-4
28. Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, et al. Short term administration of intranasal or oral hexarelin, a synthetic hexapeptide, does not desensitize the GH responsiveness in human aging. Eur J Endocrinol 1996; 135:790-5
29. Aloi JA, Gertz BJ, Hartman ML, Huhn WC, Pezzoli SS, Wittreich M, et al. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. J Clin Endocrinol Metab 1994;79:943-9
30. Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996;81:4249-57
31. Chatelain P, Claris O, Lapillonne A, Dimayo M, Salle B. Fetal and neonatal somatotroph function. Front Paediatr Neuroendocrinol 1994;20:127-30
32. Loche S, Colao A, Cappa M, Bellone J, Aimaretti G, Farello G, et al. The growth hormone response to hexarelin in children: reproducibility and effect of sex steroids. J Clin Endocrinol Metab 1997;82:861-4
33. Arvat E, Gianotti L, Broglio F, Maccagno B, Bertagna A, Deghenghi R, et al. Oestrogen replacement does not restore the reduced GH-releasing activity of hexarelin, a synthetic hexapeptide, in postmenopausal women. Eur J Endocrinol 1997;136:483-7
34. Penalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man. J Clin Endocrinol Metab 1993;76:168-71
35. Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, et al. Modulation of growth hormone-releasing activity of hexarelin in man. Neuroendocrinology 1995; 61:51-6
36. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the action of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991;128:2027-35
37. Arvat E, Gianotti L, Ramunni J, DiVito L, Deghenghi R, Camanni F, et al. Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of hexarelin in man. J Endocrinol Invest 1996;19:25-9
38. Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R, et al. Mediation of the auto-feedback mechanism on the GH-releasing effect of hexarelin, a synthetic hexapeptide, in man. Eur J Endocrinol 1997;46:83-8
39. Maccario M, Arvat E, Procopio M, Gianotti L, Grottoli S, Imbimbo BP, et al. Metabolic modulation of the growth-hormone-releasing activity of hexarelin in man. Metabolism 1995;44:134-8
40. Gertz BJ, Sciberras DG, Yogendran L, Christie K, Bador K, Krupa D, et al. L-692,429, a nonpeptide growth hormone (GH) secretagogue reverses glucocorticoid suppression of GH secretion. J Clin Endocrinol Metab 1994;79:745-9
41. Massoud AF, Hindmarsh PC, Brook CG. Hexarelin induced growth hormone release is influenced by exogenous growth hormone. Clin Endocrinol 1995;43:617-21
42. Fairhall KM, Mynett A, Robinson ICAF. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J Endocrinol 1995;144:555-60
43. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995;80:942-7
44. Loche S, Cambiaso P, Carta D, Setzu S, Imbimbo BP, Borrelli P, et al. The growth hormone-releasing activity of hexarelin, a new synthethic hexapeptide, in short normal and obese children and in hypopituitary subjects. J Clin Endocrinol Metab 1995;80:674-8
45. Clark RG, Carlsson MS, Trojnar J, Robinson ICAF. The effects of a growth hormone-releasing peptide and growth hormone-releasins factor in conscious and anaesthetized rats. J Neuroendocrinol 1989;1:252-5
46. Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 1993;77:1641-7
47. Huhn WC, Hartman ML, Pezzoli SS, Thorner MO. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 1993;76:1202-8
48. DeBell WK, Pezzoli, SS, Thorner MO. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation. J Clin Endocrinol Metab 1991;72:1312-16
49. Klinger B, Silberld A, Deghenghi R, Frenkel J, Laron Z. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur J Endocrinol 1996;134:716-19
50. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol 1995; 43:631-5
51. Adams EF, Petersen B, Lei T, Hunchfelder M, Fanlbusch R. The growth hormone secretagogue, L-692,429, induces phosphatidylinositol hydrolysis and hormone secretion by human pituitary tumors. Biochem Biophys Res Comm 1995;214:454-60
52. Renner U, Brockmeier S, Strasburger CJ, Lange M, Schopohl J, Muller OA, et al. Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide. J Clin Endocrinol Metab 1994;78:1090-6
53. Ciccarelli E, Grottoli S, Razzore P, Gianotti L, Arvat E, Deghenghi R, et al. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinemia patients. Clin Endocrinol 1996;44:67-71
54. Popovic V, Damjanovic S, Micic D, Petakov M, Dieguez C, Casanueva FF. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6. J Clin Endocrinol Metab 1994;79:456-60
55. Popovic V, Micic D, Damjanovic S, Djurovic M, Simic M, Gligorovic M, et al. Evaluation of pituitary GH reserve with GHRP-6. J Pediatr Endocrinol Metab 1996;9:289-98
56. Ramos-Dias JC, Pimentel Filho F, Reis AF, Lengyel AMJ. Different growth hormone (GH) responses to GH-releasing peptide and GH-releasing hormone in hyperthyroidism. J Clin Endocrinol Metab 1996;81:1343-6
57. Van der Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, et al. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotropin-releasing hormone in critical illness. Clin Endocrinol 1996;45:341-51
58. Pombo M, Barreiro J, Penalva A, Mallo F, Casanueva FF, Dieguez C. Plasma growth hormone response to growth hormone releasing hexapeptide (GHRP-6) in children with short stature. Acta Paediatr 1995;84:904-8
59. Leal-Cerro A, Garcia E, Astorga R, Casanueva FF, Dieguez C. Growth hormone (GH) responses to the combined administration of GH-releasing peptide 6 in adults with GH deficiency. Eur J Endocrinol 1995;132:712-15
60. Laron Z. Growth hormone secretagogues. Drugs 1995; 50:595-601
61. Cordido F, Penalva A, Peino R, Casanueva FF, Dieguez C. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6 and pyridostigmine in normal and obese subjects. Metabolism 1995;44:745-8
62. Grottoli S, Maccario M, Procopio M, Oleandri S, Razzore P, Taliano M, et al. Somatotrope responsiveness to hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity. Eur J Endocrinol 1996;135:678-82
63. 2. J Endocrinol 1989; 121:31-6
64. Leal Cerro A, Pumar A, Garcia-Garcia E, Dieguez C, Casanueva FF. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome. Clin Endocrinol 1994;41:649-54
65. Thorner MO, Hartman ML, Gaylinn BD. Current status of therapy with growth hormone-releasing neuropeptides. In: Savage MO, Bourgulgon J, Grossman AB, editors. Frontiers in paediatric neuroendocrinology. Oxford: Blakwell Scientific, 1994:161-7
66. th International Congress of Endocrinology, 1996:769 (abstract No. P3-58)